Indonesia Gets 1.2 Million COVID-19 Vaccines From China-Based Company
The Indonesian government on Sunday announced that 1.2 million doses of China’s COVID-19 vaccines from China-based company have arrived in the country.
Several countries around the world are still fighting against the deadly COVID-19 pandemic. Various countries are still awaiting the COVID-19 vaccine to stop the spread of the virus. However, the Indonesian government announced that 1.2 million doses of COVID-19 vaccine from China-based company had already arrived in the country. Indonesian President Joko Widodo made the announcement on Sunday. For all the people who are curious to know about China-made vaccines that have arrived in Indonesia, here is everything you need to know about it.
See the video here
Indonesian President Joko Widodo announced the latest news about China’s Sinovac vaccines through a televised address on Sunday, December 7, 2020. Sinovac biotech is a China-based biopharmaceutical company. During his address, he also added that another 1.8 million doses will be arriving in January next year. During his address, President Joko Widodo said, “I would like to convey the good news that today the government has received 1.2 million doses of the COVID-19 vaccine. This vaccine is made by Sinovac which we have been testing clinically in Bandung since last August 2020. We are also still working on 1.8 million doses of vaccines due in early January 2021.”
However, the people in Indonesia have to wait a little longer before the mass vaccination starts. The emergency use authorisation from the country’s food and drug control agency is still needed to do the mass vaccination in Indonesia. Once the country receives nod from drug control agency, they will be starting with the mass vaccination. The government is also awaiting the arrival of millions of other doses of Sinovac vaccines in the form of raw material. These raw materials will be further processed by state-owned pharmaceutical company.
Indonesia has already cooperated with Sinovac in their phase 3 trials of its vaccine candidate. Tests were being carried out on nearly 1600 volunteers since August. According to the head of food and drug control agency, Sinovac vaccine could obtain the emergency use authorisation by the third or fourth week of January 2021 after the agency evaluates interim results for the third stage clinical trials. The Indonesian government has also looked into probable partnerships with two other Chinese drug manufacturers Sinopharm and CanSino Biologics.